CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- 4 Open-market buy CEO and CFO bought 12,700 shares at $11.07 ($140,589)
- 8-K Event Other events
- 8-K Event Shareholder vote results
- 4 Open-market buy CEO and CFO bought 5,000 shares at $10.17 ($50,838)
- 4 Open-market buy CEO and CFO bought 3,500 shares at $9.11 ($31,885)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $8.57 ($4,285)
- 4 Open-market buy CEO and CFO bought 2,500 shares at $7.97 ($19,925)
- 4 Open-market buy CEO and CFO bought 2,500 shares at $7.91 ($19,775)
- DEFA14A Proxy Proxy Materials
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- 10-Q Report Quarterly Report
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.07 ($9,070)
- 4 Open-market buy CEO and CFO bought 2,000 shares at $8.63 ($17,260)
- 4 Open-market buy VP Clinical Reg Affairs bought 600 shares at $8.71 ($5,226)
- 4 Open-market buy CEO and CFO bought 4,000 shares at $8.95 ($35,800)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.48 ($9,480)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.97 ($9,970)
- 10-Q Report Quarterly Report
- NT 10-Q Other NT 10-Q
Page 5 of 14 · 279 filings